Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NEW YORK, March 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Argos Therapeutics, Inc. (“Argos”) (NASDAQ:ARGS) between February 7, 2014 and February 21, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Maurer v. Argos Therapeutics, Inc., et al. (Case No. 1:17-cv-216) in the USDC for the Middle District of North Carolina. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/argos-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
Argos’ product candidate AGS-003 (rocapuldencel-T) is being evaluated in a pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
Take Action: if you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
